Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bennu Pharmaceuticals, a clinical development subsidiary of Raptor Pharmaceuticals, has acquired an exclusive worldwide license to intellectual property from the University of California, San Diego, around the use of cysteamine, and delayed release cysteamine for the treatment of non-alcoholic steatohepatitis.
Subscribe to our email newsletter
In collaboration with doctors from University of California, San Diego (UCSD) School of Medicine, Bennu plans to initiate a Phase IIa clinical study of delayed release cysteamine (DR Cysteamine) in non-alcoholic steatohepatitis (NASH) patients in 2008.
Ted Daley, president of Bennu, said: “We are delighted to extend our relationship with UCSD. Additional rights to cysteamine in NASH complement our license to DR Cysteamine for cystinosis and neurodegenerative diseases.”